Temporal expression of proteoglycans in the rat limb during bone healing.

Proteoglycans found in the bone extracellular matrix and on the cell surface can complex with HBGFs such as the FGFs, TGFs and BMPs which are known to play key roles in regulating fracture healing. Here we have studied the expression of key PGs during the bone repair process in order to determine the relationship between PG expression and healing status. We created non-critical sized trephine defects just proximal to the distal end of the tibial crest of adult male Wistar rats and examined the healing process histologically as well as by monitoring the temporal expression of mRNA transcripts for ALP, OP and OC, together with HSPG, CSPG and FGF-FGF receptor expression. Following surgery, animals were allowed to recover, and then euthanized after 7, 14, 21 and 28 days post-surgery, at which time tissue was harvested for histological examination and total RNA extracted and the mRNA transcripts examined by quantitative real-time PCR. HS and CSPG expression was generally observed to increase in the days immediately following injury, reaching peak expression two weeks post-surgery. This was followed by a gradual return to basal levels by day 28. The expression patterns of PGs were broadly similar with those of ALP, OP and FGFRs. The increase of mRNA expression for many key PGs detected during bone healing coincided with the elevation of bone markers and FGFRs, and provides further evidence that PGs involved in bone repair act in part through susceptible growth factors, including the FGF/FGFR system. The data presented here indicates that increased proteoglycan expression is involved in the early stages of bone healing at a time when previous studies have shown that the levels of HBGFs are maximal. Hence there exists a rationale for an exploration of the use of exogenous PGs as an adjunct therapy to potentiate the powerful effects of these factors and to augment the natural healing response.

[1]  M. Kool,et al.  Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. , 1998, The Journal of clinical investigation.

[2]  P. Marie,et al.  Differential expression of fibroblast growth factor receptor-1, -2, and -3 and syndecan-1, -2, and -4 in neonatal rat mandibular condyle and calvaria during osteogenic differentiation in vitro. , 1999, Bone.

[3]  Yoshihiko Yamada,et al.  Role of perlecan in skeletal development and diseases , 2002, Glycoconjugate Journal.

[4]  B. Barlogie,et al.  Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. , 1998, Blood.

[5]  H. Ozawa,et al.  Immunohistochemical localization of heparan sulfate proteoglycan in rat tibiae , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  M. Detmar,et al.  Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. , 2001, The Journal of clinical investigation.

[7]  R. Timpl,et al.  Perlecan Maintains the Integrity of Cartilage and Some Basement Membranes , 1999, The Journal of cell biology.

[8]  D. Ornitz,et al.  FGFs, heparan sulfate and FGFRs: complex interactions essential for development. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[9]  M. Goldfarb,et al.  Heparin can activate a receptor tyrosine kinase. , 1995, EMBO Journal.

[10]  W. Young,et al.  Differential expression and distribution of syndecan-1 and -2 in periodontal wound healing of the rat. , 2002, Journal of periodontal research.

[11]  K. Fukada,et al.  In situ hybridization and immunohistochemistry of versican, aggrecan and link protein, and histochemistry of hyaluronan in the developing mouse limb bud cartilage , 2003, Journal of anatomy.

[12]  S. Selleck Proteoglycans and pattern formation: sugar biochemistry meets developmental genetics. , 2000, Trends in genetics : TIG.

[13]  E. Ogata,et al.  Effects of transforming growth factor β1 and l‐ascorbate on synthesis and distribution of proteoglycans in murine osteoblast‐like cells , 1993 .

[14]  G. Carpentier,et al.  Heparan-like molecules induce the repair of skull defects. , 1995, Bone.

[15]  J. Heath,et al.  Fgfr2 and osteopontin domains in the developing skull vault are mutually exclusive and can be altered by locally applied FGF2. , 1997, Development.

[16]  T Matsumoto,et al.  Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity. , 1994, The Journal of biological chemistry.

[17]  E. Vuorio,et al.  A standardized experimental fracture in the mouse tibia , 1993, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[18]  E. Canalis,et al.  Skeletal growth factors. , 2000, Critical reviews in eukaryotic gene expression.

[19]  D. Lane,et al.  Heparin and Related Polysaccharides , 1992, Advances in Experimental Medicine and Biology.

[20]  T. Einhorn,et al.  Spatial and temporal gene expression for fibroblast growth factor type I receptor (FGFR1) during fracture healing in the rat. , 2001, Bone.

[21]  I. Takahashi,et al.  Expression of Versican and ADAMTS1, 4, and 5 During Bone Development in the Rat Mandible and Hind Limb , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[22]  E. Mackie,et al.  Establishment of a Model of Cortical Bone Repair in Mice , 2003, Calcified Tissue International.

[23]  A. Lander,et al.  Expression of the heparan sulfate proteoglycan glypican‐1 in the developing rodent , 1998, Developmental dynamics : an official publication of the American Association of Anatomists.

[24]  J O Hollinger,et al.  The critical size defect as an experimental model for craniomandibulofacial nonunions. , 1986, Clinical orthopaedics and related research.

[25]  J. Hecht,et al.  Expression of the Heparan Sulfate Proteoglycan, Perlecan, during Mouse Embryogenesis and Perlecan Chondrogenic Activity In Vitro , 1999, The Journal of cell biology.

[26]  T. Einhorn,et al.  Spatial and temporal distribution of CD44 and osteopontin in fracture callus. , 1999, The Journal of bone and joint surgery. British volume.

[27]  R. Midura,et al.  Plasma-membrane-intercalated heparan sulphate proteoglycans in an osteogenic cell line (UMR 106-01 BSP). , 1992, Biochemical Journal.

[28]  M. Young,et al.  Deduced protein sequence of bone small proteoglycan I (biglycan) shows homology with proteoglycan II (decorin) and several nonconnective tissue proteins in a variety of species. , 1989, The Journal of biological chemistry.

[29]  J. Heath,et al.  Functions of fibroblast growth factors and their receptors , 1995, Current Biology.

[30]  E. Ruoslahti,et al.  Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. , 1994, The Biochemical journal.

[31]  P. Leder,et al.  Fibroblast Growth Factor Receptor 3 Is a Negative Regulator of Bone Growth , 1996, Cell.

[32]  G. Karsenty,et al.  Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation , 1997, Cell.

[33]  M. Klagsbrun,et al.  A dual receptor system is required for basic fibroblast growth factor activity , 1991, Cell.

[34]  L. Gold,et al.  New concepts in tissue repair: skin as an example. , 1996, Diabetes & metabolism.

[35]  T A Einhorn,et al.  Growth Factor Regulation of Fracture Repair , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[36]  Mark E. Bolander,et al.  Regulation of Fracture Repair by Growth Factors , 1992, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[37]  G. David,et al.  Structural and functional diversity of the heparan sulfate proteoglycans. , 1992, Advances in experimental medicine and biology.

[38]  L. Sandell,et al.  Extracellular matrix gene regulation. , 2004, Clinical orthopaedics and related research.

[39]  Yoshihiko Yamada,et al.  Perlecan is essential for cartilage and cephalic development , 1999, Nature Genetics.

[40]  J B Lian,et al.  Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. , 1989, Physiological reviews.

[41]  W. Hornebeck,et al.  FGF protection and inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives. , 1996, International Journal of Biological Macromolecules.

[42]  C. Stuelten,et al.  Extracellular Matrix Proteoglycans Control the Fate of Bone Marrow Stromal Cells* , 2005, Journal of Biological Chemistry.

[43]  E. Ruoslahti,et al.  Negative regulation of transforming growth factor-β by the proteoglycan decorin , 1990, Nature.

[44]  Arnold Munnich,et al.  Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia , 1994, Nature.

[45]  E. Canalis,et al.  Effects of basic fibroblast growth factor on bone formation in vitro. , 1988, The Journal of clinical investigation.

[46]  G. Karsenty,et al.  Osteocalcin cluster: Implications for functional studies , 1995, Journal of cellular biochemistry.

[47]  D. Gospodarowicz,et al.  Cultured bovine bone cells synthesize basic fibroblast growth factor and store it in their extracellular matrix. , 1989, Endocrinology.

[48]  S A Goldstein,et al.  Aggrecan core protein is expressed in membranous bone of the chick embryo. Molecular and biomechanical studies of normal and nanomelia embryos. , 1992, The Journal of biological chemistry.

[49]  Jay R Lieberman,et al.  The role of growth factors in the repair of bone. Biology and clinical applications. , 2002, The Journal of bone and joint surgery. American volume.

[50]  E. Jabs,et al.  Mutations in fibroblast growth factor receptors: phenotypic consequences during eukaryotic development. , 1995, American journal of human genetics.

[51]  E. Ogata,et al.  Isolation and characterization of proteoglycans synthesized by mouse osteoblastic cells in culture during the mineralization process. , 1990, The Biochemical journal.

[52]  W. Knudson,et al.  Cartilage proteoglycans. , 2001, Seminars in cell & developmental biology.

[53]  M. Young,et al.  Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[54]  E. Ruoslahti Proteoglycans in cell regulation. , 1989, Journal of Biological Chemistry.

[55]  Kozo Nakamura,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Acceleration of Fracture Healing in Nonhuman Primates by Fibroblast Growth Factor-2 , 2022 .

[56]  W. Wilcox,et al.  Dyssegmental dysplasia, Silverman-Handmaker type: Unexpected role of perlecan in cartilage development# , 2001 .

[57]  H. Kleinman,et al.  Proteoglycans of developing bone. , 1983, The Journal of biological chemistry.

[58]  Benjamin M. Wu,et al.  Bone morphogenetic protein 2 and retinoic acid accelerate in vivo bone formation, osteoclast recruitment, and bone turnover. , 2005, Tissue engineering.

[59]  R. Gamelli,et al.  Heparin and heparan sulphate protect basic fibroblast growth factor from non-enzymic glycosylation. , 1999, The Biochemical journal.

[60]  Erkki Ruoslahti,et al.  Proteoglycans as modulators of growth factor activities , 1991, Cell.

[61]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[62]  M. Stepp,et al.  Defects in keratinocyte activation during wound healing in the syndecan-1-deficient mouse , 2002, Journal of Cell Science.